News coverage about CONMED (NASDAQ:CNMD) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. CONMED earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned news coverage about the medical technology company an impact score of 46.4885952488433 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

A number of research analysts have recently commented on the company. BidaskClub cut CONMED from a “hold” rating to a “sell” rating in a research report on Tuesday, December 12th. Needham & Company LLC reaffirmed a “buy” rating and set a $58.00 price target on shares of CONMED in a research report on Friday, November 17th. Zacks Investment Research raised CONMED from a “sell” rating to a “hold” rating in a research report on Tuesday, November 14th. KeyCorp reaffirmed a “hold” rating on shares of CONMED in a research report on Friday, November 3rd. Finally, Piper Jaffray Companies reaffirmed a “hold” rating and set a $46.00 price target on shares of CONMED in a research report on Friday, November 3rd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $50.67.

Shares of CONMED (NASDAQ:CNMD) opened at $50.50 on Friday. The stock has a market capitalization of $1,430.00, a PE ratio of 28.55, a P/E/G ratio of 3.20 and a beta of 0.66. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.49 and a current ratio of 2.56. CONMED has a 1-year low of $39.74 and a 1-year high of $54.77.

CONMED (NASDAQ:CNMD) last issued its quarterly earnings data on Thursday, November 2nd. The medical technology company reported $0.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.01. The business had revenue of $190.10 million for the quarter, compared to analysts’ expectations of $187.13 million. CONMED had a return on equity of 8.40% and a net margin of 1.99%. The firm’s quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.41 EPS. analysts expect that CONMED will post 1.84 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 5th. Investors of record on Friday, December 15th will be issued a dividend of $0.20 per share. The ex-dividend date is Thursday, December 14th. This represents a $0.80 dividend on an annualized basis and a yield of 1.58%. CONMED’s dividend payout ratio (DPR) is 145.45%.

In other CONMED news, EVP Luke A. Pomilio sold 29,363 shares of the firm’s stock in a transaction dated Thursday, November 9th. The stock was sold at an average price of $50.70, for a total value of $1,488,704.10. Following the sale, the executive vice president now owns 45,486 shares of the company’s stock, valued at approximately $2,306,140.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Luke A. Pomilio sold 10,020 shares of the firm’s stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $53.57, for a total value of $536,771.40. Following the completion of the sale, the executive vice president now directly owns 44,472 shares in the company, valued at approximately $2,382,365.04. The disclosure for this sale can be found here. Insiders have sold a total of 51,812 shares of company stock worth $2,654,756 in the last three months. 2.62% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact CONMED (CNMD) Stock Price” was reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.watchlistnews.com/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-conmed-cnmd-stock-price/1768936.html.

CONMED Company Profile

CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.

Insider Buying and Selling by Quarter for CONMED (NASDAQ:CNMD)

Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.